ArticleAntiviral research2010
Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice.
Article in Antiviral research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Engineering viral protease-operated nanobodies for programmable and orthogonal control of protein function.Nature communications · 2026Article
- Longitudinal trajectories of weight changes among people living with HIV on antiretroviral therapy: A group-based study.iScience · 2023Article
- Summarizing studies using constitutive genetic deficiency to investigate behavioural influences of uptake 2 monoamine transporters.Basic & clinical pharmacology & toxicology · 2023Review
- HIV Transgenic Rats Demonstrate Superior Task Acquisition and Intact Reversal Learning in the Within-Session Probabilistic Reversal Learning Task.Cognitive, affective & behavioral neuroscience · 2021Article
- HIV Transgenic Rats Demonstrate Impaired Sensorimotor Gating But Are Insensitive to Cannabinoid (Δ9-Tetrahydrocannabinol)-Induced Deficits.The international journal of neuropsychopharmacology · 2021Article
- Neurological complications of COVID-19: from pathophysiology to rehabilitation. An overview.Acta bio-medica : Atenei Parmensis · 2021Article
- Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19).Diabetes/metabolism research and reviews · 2021Review
- Neurologic complications of COVID-19.The American journal of emergency medicine · 2020Review
- Antiretroviral Therapy-Associated Metabolic Complications: Review of the Recent Studies.HIV/AIDS (Auckland, N.Z.) · 2020Review
- Anticancer and Differentiation Properties of the Nitric Oxide Derivative of Lopinavir in Human Glioblastoma Cells.Molecules (Basel, Switzerland) · 2018Article
- Constitutive plasma membrane monoamine transporter (PMAT, Slc29a4) deficiency subtly affects anxiety-like and coping behaviours.The European journal of neuroscience · 2018Article
- Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice.Experimental and therapeutic medicine · 2018Article
- Evaluation of Oral Antiretroviral Drugs in Mice With Metabolic and Neurologic Complications.Frontiers in pharmacology · 2018Article
- Article
- Predicting neurological Adverse Drug Reactions based on biological, chemical and phenotypic properties of drugs using machine learning models.Scientific reports · 2017Article
- Antiretroviral Treatment in HIV-1-Positive Mothers: Neurological Implications in Virus-Free Children.International journal of molecular sciences · 2017Review
- Article
- HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via β-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation.The American journal of pathology · 2017Article
- Neuroprotection mediated by inhibition of calpain during acute viral encephalitis.Scientific reports · 2016Article
- HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance.AIDS (London, England) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
It is well established that HIV antiretroviral drugs, particularly protease inhibitors, frequently elicit a metabolic syndrome that may include hyperlipidemia, lipodystrophy, and insulin resistance. Metabolic dysfunction in non-HIV-infected subjects has been repeatedly associated with cognitive impairment in epidemiological and experimental studies, but it is not yet understood if antiretroviral therapy-induced metabolic syndrome might contribute to HIV-associated neurologic decline. To determine if protease inhibitor-induced metabolic dysfunction in mice is accompanied by adverse neurologic effects, C57BL/6 mice were given combined lopinavir/ritonavir (50/12.5-200/50 mg/kg) daily for 3 weeks. Data show that lopinavir/ritonavir administration caused significant metabolic derangement, including alterations in body weight and fat mass, as well as dose-dependent patterns of hyperlipidemia, hypoadiponectinemia, hypoleptinemia, and hyperinsulinemia. Evaluation of neurologic function revealed that even the lowest dose of lopinavir/ritonavir caused significant cognitive impairment assessed in multi-unit T-maze, but did not affect motor functions assessed as rotarod performance. Collectively, our results indicate that repeated lopinavir/ritonavir administration produces cognitive as well as metabolic impairments, and suggest that the development of selective aspects of metabolic syndrome in HIV patients could contribute to HIV-associated neurocognitive disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.